Madison, Wisconsin-based Asthmapolis, which offers an FDA-cleared inhaler sensor and companion app, announced a deal with San Diego-based Sharp Rees-Stealy Medical Centers. The hospital will offer the Asthmapolis platform as part of its asthma respiratory health management program.
Asthmapolis’ device is a sensor that attaches to most inhalers for patients who have asthma or COPD. The sensor transmits data to an app every time the inhaler is used and the system records the time and location. The resulting report is available to physicians and patients. Asthmapolis also provides email or text reminders are sent to patients to help them remember to take their medication.
“Until now we have been really focused on building the product and demonstrating efficacy, which we have done,” Asthmapolis CEO and co-founder David Van Sickle told MobiHealthNews in an interview this past April. “We are in the market, as you know, and now it is time to scale up and meet these populations wherever they are. Asthma isn’t a disease of just a certain demographic or geography — it is a part of every population.”
Earlier this year, Asthmapolis raised $5 million from Social + Capital Partnership in order to fund plans to secure regulatory clearances in countries outside the US like Canada and the UK.